Setrusumab - Mereo BioPharma

Drug Profile

Setrusumab - Mereo BioPharma

Alternative Names: BPS-804

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Mereo BioPharma; Novartis
  • Class Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteogenesis imperfecta
  • Discontinued Hypophosphatasia; Postmenopausal osteoporosis

Most Recent Events

  • 22 Dec 2017 Mereo BioPharma withdraws the phase II METEOROID trial in Osteogenesis imperfecta in USA (NCT03216486)
  • 13 Dec 2017 Mereo Biopharma submits Paediatric Investigation Plan (PIP) for setrusumab to the Paediatric committee of the European Medicines Agency (PDCO) for two clinical studies in Osteogenesis imperfecta
  • 13 Dec 2017 Mereo BioPharma plans a phase IIb/III study of setrusumab in Osteogenesis imperfecta (In children, In adolescents) in Europe and Canada in the second half of 2018 ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top